Dermira, Inc. (NASDAQ:DERM) CEO Thomas G. Wiggans sold 9,500 shares of the company’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $27.51, for a total transaction of $261,345.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Thomas G. Wiggans also recently made the following trade(s):

  • On Tuesday, August 1st, Thomas G. Wiggans sold 500 shares of Dermira stock. The stock was sold at an average price of $27.58, for a total transaction of $13,790.00.
  • On Monday, July 3rd, Thomas G. Wiggans sold 5,000 shares of Dermira stock. The stock was sold at an average price of $29.06, for a total transaction of $145,300.00.

Dermira, Inc. (NASDAQ:DERM) traded down 0.58% during trading on Tuesday, reaching $27.36. 450,238 shares of the company’s stock traded hands. The company has a 50-day moving average price of $24.55 and a 200 day moving average price of $29.49. Dermira, Inc. has a one year low of $21.35 and a one year high of $38.75. The firm’s market capitalization is $1.14 billion.

Dermira (NASDAQ:DERM) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.04). Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.00 million. On average, analysts anticipate that Dermira, Inc. will post ($4.20) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/19/thomas-g-wiggans-sells-9500-shares-of-dermira-inc-derm-stock.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA boosted its stake in Dermira by 2,220.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 3,975 shares during the last quarter. SG Americas Securities LLC boosted its stake in Dermira by 66.8% during the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 2,203 shares during the last quarter. KCG Holdings Inc. acquired a new stake in Dermira during the 1st quarter worth $215,000. Legal & General Group Plc boosted its stake in Dermira by 16.3% during the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 963 shares during the last quarter. Finally, RidgeWorth Capital Management LLC acquired a new stake in Dermira during the 1st quarter worth $297,000. 97.54% of the stock is currently owned by institutional investors.

A number of equities analysts recently weighed in on DERM shares. BidaskClub upgraded shares of Dermira from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Needham & Company LLC restated a “buy” rating and set a $46.00 target price on shares of Dermira in a research report on Tuesday, July 18th. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Evercore ISI started coverage on shares of Dermira in a research report on Thursday, June 29th. They set an “outperform” rating and a $48.00 target price for the company. Finally, Cantor Fitzgerald started coverage on shares of Dermira in a research report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 target price for the company. Four investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Dermira has a consensus rating of “Hold” and an average target price of $44.40.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.